Genkyotex Company Profile
Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. A Series C round was closed in 2011 led by Edmond de Rothschild Investment Partners and joined by other new investors Vesalius BioCapital and MP Healthcare Venture Management. Further information can be found at: www.genkyotex.com.
News Articles
Genkyotex étend son série C de 20,8 M
Les big rounds s’enchaînent à grande vitesse pour la biotech franco-suisse Genkyotex. Après une levée de 14,5 M fédérée en mai 2011…
Genkyotex's First in Class NOX Inhibitor GKT137831 to Be Presented at Kidney Week
GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Oct 15, 2012 - Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and m...
Genkyotex's Lead NOX Inhibitor GKT137831 Demonstrates Activity in Models of Liver Fibrosis
Data Published in Hepatology GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Aug 8, 2012 - Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today...
Genkyotex picks up extra CHF25M to advance diabetic nephropathy candidate
Armed with positive Phase I data of its lead NOX inhibitor program, Swiss biotech Genkyotex has picked up an additional CHF25 million ($26 million) from its existing investors to extend the am...
Genkyotex picks up extra CHF25M to advance diabetic neuropathy candidate
Armed with positive Phase I data of its lead NOX inhibitor program, Swiss biotech Genkyotex has picked up an additional CHF25 million ($26 million) from its existing investors to extend the amount rai...
Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012
Single- and Multi-Dose Data Shows Excellent Safety and Pharmacokinetic Profiles GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Nov 2, 2012 - Genkyotex, the leading developer of NOX inhibitors to trea...
Genkyotex’s First in Class NOX Inhibitor GKT137831 to Be Presented at Kidney Week
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX...
Genkyotex Raises CHF25 Million in Series C Round Extension
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Serie...
Drugs and Medications
None
PubMed Articles
We describe the design, synthesis, and optimization of first-in-class series of inhibitors of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulm...
Clinical Trials
None
Companies
Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyot...
More Information about "Genkyotex" on BioPortfolio
We have published hundreds of Genkyotex news stories on BioPortfolio along with dozens of Genkyotex Clinical Trials and PubMed Articles about Genkyotex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genkyotex Companies in our database. You can also find out about relevant Genkyotex Drugs and Medications on this site too.
